• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Vaccines for Zaire Ebola virus disease are safe and generate an immune response

byDavid XiangandKiera Liblik
January 4, 2023
in Emergency, Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this trial for the safety of vaccines used to prevent Zaire Ebola virus disease (EVD), no concerns were identified.

2. All three vaccine regimens tested demonstrated immune responses by day 14 lasting through to month 12. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: EVD outbreaks have high morbidity and mortality, and have recently recurred in the Democratic Republic of Congo and Guinea. Two vaccine strategies to prevent EVD have received World Health Organization (WHO) prequalification status and were used during the most recent Ebola outbreaks. The strategies include the recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the surface glycoprotein of Zaire ebolavirus (ZEBOV; the rVSVΔG-ZEBOV-GP vaccine) and the combination of an adenovirus type 26–vectored vaccine encoding the ZEBOV glycoprotein (Ad26.ZEBOV) followed by a booster dose of a modified vaccinia Ankara virus strain (MVA-BN-Filo). However, there is a gap in knowledge as to understanding the safety of these vaccines, as well as the rapidity and durability of antibody responses to them. Overall, this study found that immune responses were elicited within 14 days of injection for these vaccine regimens and were maintained for 12 months, and no safety concerns were identified. This study was limited by being unable to assess protection from disease or determining a correlate of protection. Nevertheless, these study’s findings are significant, as they demonstrate that vaccines for the prevention of EVD are efficacious in eliciting an immune response and have no reportable safety concerns.

Click to read the study in NEJM

Relevant Reading: A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

RELATED REPORTS

High-Dose Docosahexaenoic Acid Does Not Improve Behavioral Functioning in Preterm Infants at 5 Years of Age

2 Minute Medicine Rewind November 27, 2023

Pulsed-field noninferior to thermal ablation in treating paroxysmal atrial fibrillation

In-Depth [randomized controlled trial]: Two randomized, placebo-controlled trials were conducted, with one involving adults and one involving children. Three vaccine regimens were tested: Ad26.ZEBOV followed by MVA-BN-Filo 56 days later (the Ad26–MVA group), rVSVΔG-ZEBOV-GP followed by placebo 56 days later (the rVSV group), and rVSVΔG-ZEBOV-GP followed by rVSVΔG-ZEBOV-GP 56 days later (the rVSV–booster group). Adults who were 18 years of age or older and children 1 to 17 years of age, all without a history of EVD, and who were not pregnant or breastfeeding were eligible for the study. The primary outcome measured was antibody response at 12 months, defined as having both a 12-month antibody concentration of at least 200 enzyme-linked immunosorbent assay units (EU) per milliliter and an increase from baseline in the antibody concentration by at least a factor of four. Based on the primary analysis, the incidence of injection-site reactions and symptoms (feverishness and headache) was higher in the week after receipt of the primary and second or booster vaccinations than after receipt of placebo but not at later time points. At month 12, a total of 41% of adults (titer, 401 EU per milliliter) and 78% of children (titer, 828 EU per milliliter) had a response in the Ad26–MVA group; 76% (titer, 992 EU per milliliter) and 87% (titer, 1415 EU per milliliter), respectively, had a response in the rVSV group; 81% (titer, 1037 EU per milliliter) and 93% (titer, 1745 EU per milliliter), respectively, had a response in the rVSV–booster group; and 3% (titer, 93 EU per milliliter) and 4% (titer, 67 EU per milliliter), respectively, had a response in the placebo group (p<0.001 for all comparisons of vaccine with placebo). Overall, this study demonstrates that no safety concerns were identified and all three vaccine regimens demonstrated an immune response against EVD.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ebolaebola outbreakemergencyinfectious diseasepediatricspublic healthvaccinationvaccine regimensWHOworld health organizationZaire Ebola virus disease
Previous Post

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

Next Post

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

RelatedReports

Digital imaging detects sight-threatening retinopathy of prematurity
Pediatrics

High-Dose Docosahexaenoic Acid Does Not Improve Behavioral Functioning in Preterm Infants at 5 Years of Age

November 29, 2023
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Weekly Rewinds

2 Minute Medicine Rewind November 27, 2023

November 27, 2023
Lariat device for left atrial appendage exclusion associated with adverse events
Cardiology

Pulsed-field noninferior to thermal ablation in treating paroxysmal atrial fibrillation

November 24, 2023
Of Background Image
Infectious Disease

Vancomycin and cefazolin not superior to cefazolin alone in arthroplasty prophylaxis

November 24, 2023
Next Post
Similar outcomes after supracervical vs. total hysterectomy

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

Early palliative care may improve survival in advanced cancer

Wellness Check: Spirituality

2 Minute Medicine Rewind October 14, 2019

Haloperidol does not improve outcomes at 90 days in ICU patients with delirium

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The 2 Minute Medicine Podcast Episode 29
  • #VisualAbstract: Erdafitinib may improve clinical outcomes compared to chemotherapy in patients with advanced urothelial carcinoma
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options